Hormonal therapy in women, thromboembolic complications and laboratory characteristics of the hemostasis system for personalized solutions

Abstract

The use of hormonal drugs for contraception and menopausal replacement therapy is widespread throughout the world. However, the use of these drugs is associated with an increased risk of thromboembolic complications (TEO). At present, it has been established that the most important cause of feasibility study is the initial, sometimes hidden, violations of the hemostasis system, predisposing to increased blood clotting and thrombosis. Their timely identification helps to personalize the use of the necessary hormonal therapy.